Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in Advanced Hepatocellular Carcinoma
NCT05171439Phase 2Unknown
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in hepatocellular carcinoma (HCC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Regulation of immune microenvironment in hepatocellular carcinoma. Status: unknown.
02
Drugs
surufatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05171439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171439.